Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
À¶Ý®ÊÓƵ
ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Miklos, D., Bharadwaj, S., Holmes, H., Oluwole, O., Jallouk, A., Neelapu, S., Jain, N., Nath, R., Munoz, J., Bryan, L., De Vos, S., Eradat, H., Patel, R., Tees, M., Tsai, S., Cahill, K., Sohl, M., Shouse, G., Stevens, D., Fisher, P., Feng, A., Severyn, C., Le Gall, J., Locke, F., Pinilla, J. CIG MEDIA GROUP, LP. 2024: S604View details for